Sisram Medical Ltd (HKG:1696)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	70.23	70.6	81.55	153.06	116.53
Short-Term Investments	2.18	0.7	9.95	4.9	2.56
Trading Asset Securities	1.75	-	-	-	-
Cash & Short-Term Investments	74.16	71.3	91.49	157.96	119.08
Cash Growth	4.01%	-22.07%	-42.08%	32.65%	7.91%
Accounts Receivable	80.76	83.46	80.38	69.88	46.5
Other Receivables	3.78	10.8	-	-	0.98
Receivables	84.54	94.25	80.38	69.88	47.48
Inventory	81.02	80.55	74.72	64.24	37.19
Prepaid Expenses	3.02	4.29	-	-	-
Other Current Assets	6.49	6.96	3.97	5.53	1.4
Total Current Assets	249.21	257.35	250.57	297.6	205.15
Property, Plant & Equipment	59.47	62.91	52.2	45.46	46.16
Long-Term Investments	7.92	6.16	16.41	7.17	0.17
Goodwill	126.92	126.92	111.18	111.18	111.18
Other Intangible Assets	142.54	136.07	45.29	51.22	53.28
Long-Term Accounts Receivable	26.55	12.91	13.05	12.55	10.62
Long-Term Deferred Tax Assets	9.62	9.94	7.25	4.7	5.05
Other Long-Term Assets	5.03	1.26	59.66	0.25	0.2
Total Assets	627.26	613.5	555.6	530.13	431.81
Accounts Payable	13.36	8	13.34	13.02	9.44
Accrued Expenses	43.36	41.13	39.56	39.6	20.39
Short-Term Debt	4.8	4.42	5.74	7.29	1.13
Current Portion of Long-Term Debt	-	-	-	-	0.38
Current Portion of Leases	4.41	4.72	2.88	3.09	2.82
Current Income Taxes Payable	8.88	4.92	1.83	4.06	-
Current Unearned Revenue	15.6	15.9	14.38	15.04	8.18
Other Current Liabilities	5.09	9.15	2.41	1.45	12.44
Total Current Liabilities	95.49	88.25	80.13	83.56	54.79
Long-Term Debt	-	-	-	-	0.18
Long-Term Leases	34	35.54	32.72	31.24	32.55
Long-Term Unearned Revenue	1.25	0.85	0.59	0.26	0.22
Long-Term Deferred Tax Liabilities	8.67	14.36	8.65	9.41	9.91
Other Long-Term Liabilities	1.74	3.76	0.24	0.32	0.46
Total Liabilities	142.47	143.98	123.38	126.51	99.92
Common Stock	1.33	1.33	1.33	1.33	1.25
Additional Paid-In Capital	323.07	323.07	321.53	319.87	240.77
Retained Earnings	171.77	156.33	135.63	104.25	76.82
Comprehensive Income & Other	-32.14	-28.42	-27.62	-23.26	13.05
Total Common Equity	464.03	452.31	430.87	402.18	331.89
Minority Interest	20.76	17.21	1.35	1.44	-
Shareholders' Equity	484.79	469.53	432.23	403.63	331.89
Total Liabilities & Equity	627.26	613.5	555.6	530.13	431.81
Total Debt	43.2	44.68	41.34	41.62	37.06
Net Cash (Debt)	30.95	26.62	50.15	116.34	82.02
Net Cash Growth	16.29%	-46.93%	-56.89%	41.85%	-16.44%
Net Cash Per Share	0.07	0.06	0.11	0.26	0.19
Filing Date Shares Outstanding	468.34	468.34	467.29	466.16	442.16
Total Common Shares Outstanding	468.34	468.34	467.29	466.16	442.16
Working Capital	153.73	169.1	170.44	214.04	150.36
Book Value Per Share	0.99	0.97	0.92	0.86	0.75
Tangible Book Value	194.57	189.33	274.4	239.78	167.43
Tangible Book Value Per Share	0.42	0.40	0.59	0.51	0.38
Machinery	21.75	20.42	17.64	13.15	9.35
Leasehold Improvements	17.44	16.04	9.9	9.77	9.6

Source: S&P Global Market Intelligence. Standard template. Financial Sources.